This Technology Is Transforming Modern Medicine
A new field of medicine is commanding the attention of pharmaceutical powerhouses, and it could be the hottest investment opportunity of the year.
When GlaxoSmithKline (NYSE: GSK) and Google (NASDAQ: GOOGL) parent Alphabet announced plans to launch a $715 Million Bioelectronics Firm last fall, it triggered a surge of interest from the biotech community. Energy technologies currently make up less than 1% of the $2.2 trillion healthcare industry, but a major shift is in motion. Striking clinical and scientific studies point to bioelectronics as the future of medical treatment and innovators like CellMedX (OTCQB: CMXC) are at the forefront of who to watch.
So what is electromedicine?
It’s actually quite simple. The human body is a complex electrochemical system. Energy disturbances can cause abnormal cell growth, leading many down the path towards chronic disease. Low-level electrical currents can be used to correct these energy disturbances, helping to alleviate pathologies in the body.
Treating medical disorders with electrical impulses rather than chemicals is not an entirely new idea. Just think of pacemakers, which use pulses of electricity to trigger the heartbeat. Or microcurrent technology, which has also long been used for the treatment of chronic pain.
It’s the application of these technologies that’s being redefined, and is opening up a wealth of opportunity for investors. Using electrical currents for the treatment of disorders like Diabetes, Parkinson’s disease, and high blood pressure is a novel concept. That’s exactly why the growth potential for early stage development companies in this space is off the charts. It is only a matter of time before others follow the lead of pioneers like Alphabet, GSK, and CellMedX.
Google parent Alphabet is extending their reach far beyond the search engine, as evidenced in their recent joint venture with GSK, Galvani Bioelectronics. Alphabet’s life science divisions, Verily and Calico, are tasked with finding the intersection between technology and medicine. From handheld electronic devices capable of diagnosing diseases within seconds, to harnessing the biology that controls lifespan, initial projects are highly ambitious.
GlaxoSmithKline (NYSE: GSK)
Pharmaceutical heavyweight, GSK has been the vanguard in electromedical research and development for years. In a Nature medical journal back in 2013, Kristoffer Famm offered his glowing endorsement of this emerging technology:
“At GlaxoSmithKline (GSK) and in academia, we are confident that this field will deliver real medicines, and we are mobilizing resources for this journey.”
Famm went on to add, “These treatments will modulate the neural impulses controlling the body, repair lost function and restore health. They could, for example, coax insulin from cells to treat diabetes, regulate food intake to treat obesity and correct balances in smooth-muscle tone to treat hypertension and pulmonary diseases.”
These claims mark a pivotal shift in thinking about medicine, one that is drawing the eyes of the pharmaceutical industry and investors alike.
CellMedX (OTCQB: CMXC)
Wall Street hasn’t taken notice yet, but this undervalued gem has just developed what may be the biggest diabetes breakthrough in over 90 years. Since the discovery of insulin in 1924, there has been very little fundamental progress in treatment – until CellMedX (CMXC) unveiled eBalance!
This revolutionary device uses a microcurrent-stimulation process that does the work of a healthy metabolism to reduce numbness, tingling or pain in arms or legs of diabetic patients. Amazingly, the company believes it can also improve glucose control, insulin resistance and blood pressure issues. It works by delivering a low-level current within a defined therapeutic protocol tailored to each individual patient. Early observations show that eBalance has already shown very positive results in insulin dependent diabetics. They’re not wasting any time either. Just one short week later, they announced that they’ve already begun screening for subjects.
But the really big news was the announcement CellMedX made on March 1, 2017, that eBalance has received the go ahead in Canada for clinical trials for Type 1 and Type 2 diabetics.
Medical stocks, like hi-tech stocks, tend to SOAR on clinical trial news and with CellMedX trading in the high $0.20s, the stock could easily become a huge multiplier!
Normally, any new diabetic treatment can take YEARS to develop; yet CellMedX has their sights set on the near-term. We can anticipate lots of clinical updates, milestones, catalysts to get the stock moving. That’s why I believe CMXC could easily be my next ten-bagger.
Here’s our take on CMXC… Canada’s medical testing is not near as strict or lengthy as it is in the USA, for one. That means CMXC is most likely poised to enter the market within a year and that spells cash flow for CellMedX and VERY HIGH potential returns for savvy shareholders.
The market for diabetes treatments is HUGE
Currently, 320 million people suffer from diabetes and that body-count is poised to DOUBLE by 2030. By 2035, one in ten people will be diagnosed with diabetes. It’s becoming one of the more serious medical dilemmas on a GLOBAL SCALE.
Nearly 12% of global healthcare expenditures were directly attributed to diabetes – in 2010 – and that number is GROWING. Diabetes health expenditures are forecast to exceed FIVE HUNDRED BILLION DOLLARS by 2035 globally. On average, it cost $703 per person globally in 2010 to treat diabetes.
That’s a lot of cash for treatments that don’t provide a cure. Most treatments involve some form of insulin use, which only helps to maintain a diabetic’s health – it does NOT SLOW THE PROGRESSION OF THE DISEASE.
CellMedX believes that the company’s electro-stimulation process – eBalance – COULD slow the progression of this disease and limit the pain and discomfort diabetics suffer from.
If CMXC can carve off even a sliver of the billions swirling around the diabetic industry, shareholders will feel the impact.
Let Me Give You Five Reasons to Buy CellMedX (CMXC) Immediately
- There is nothing available like the eBalance Device. This is a major point. Few companies can make this statement. Coke can’t. McDonald’s can’t. Having an exclusive is an enormous advantage.
- Diabetes treatment is being brought into the 21st century by combating it with mild electricity. There is already a long list of serious ailments successfully using electromedicine as a treatment. Now it’s diabetes turn.
- People are sick and tired or drugs as the answer. The trend toward using natural, non-drug options has NEVER been stronger. Scientific studies now confirm that these treatments are far better than drugs, without the risky side effects.
- CellMedX is led by a strong management and advisory team, partnering with external consultants and medical research firms. Their top-of the line leadership is a true test of how serious this company is.
- $0.20 to $0.30 a share is a remarkably low price for what they’ve already accomplished in this growing field. Considering the industry potential, their innovative product, and the soon-to-commence clinical trials, this stock is truly under the radar.
CMXC stock trades in a tight range and there are only 40.2 million shares issued and outstanding. Current trading volume averages 30,000 shares per day, yet medical stock investors aren’t even aware of CellMedX – until NOW>
So, if you own any pharma/medical stock, it should be CMXC. Check out their site and see for yourself the BIG POTENTIAL for this electromedical stock. That ticker, once again is OTCQB: CMXC >>> go get some of it and hang on for the ride of your life!
1-2. Famm, Kristoffer Famm, Brian Litt, Kevin J. Tracey, Edward S. Boyden, and Moncef Slaoui. “Drug discovery: A jump-start for electroceuticals.” Nature 496.161 (2013): Nature. Web. 08 Mar. 2017. http://www.nature.com/nature/journal/v496/n7444/full/496159a.html.
Take a look at The Chart
Download Now CellMedX-Presentation
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: